Neovessel formation promotes liver fibrosis via providing latent transforming growth factor-β

Kotaro Sakata, Satoshi Eda, Eun Seo Lee, Mitsuko Hara, Masaya Imoto, Soichi Kojima

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Aim Hepatic fibrosis and angiogenesis occur in parallel during the progression of liver disease. Fibrosis promotes angiogenesis via inducing vascular endothelial growth factor (VEGF) from the activated hepatic stellate cells (HSCs). In turn, increased neovessel formation causes fibrosis, although the underlying molecular mechanism remains undetermined. In the current study, we aimed to address a role of endothelial cells (ECs) as a source of latent transforming growth factor (TGF)-β, the precursor of the most fibrogenic cytokine TGF-β. Methods After recombinant VEGF was administered to mice via the tail vein, hepatic angiogenesis and fibrogenesis were evaluated using immunohistochemical and biochemical analyses in addition to investigation of TGF-β activation using primary cultured HSCs and liver sinusoidal ECs (LSECs). Results In addition to increased hepatic levels of CD31 expression, VEGF-treated mice showed increased α-smooth muscle actin (α-SMA) expression, hepatic contents of hydroxyproline, and latency associated protein degradation products, which reflects cell surface activation of TGF-β via plasma kallikrein (PLK). Liberating the PLK-urokinase plasminogen activator receptor complex from the HSC surface by cleaving a tethering phosphatidylinositol linker with its specific phospholipase C inhibited the activating latent TGF-β present in LSEC conditioned medium and subsequent HSC activation. Conclusion Neovessel formation (angiogenesis) accelerates liver fibrosis at least in part via provision of latent TGF-β that activated on the surface of HSCs by PLK, thereby resultant active TGF-β stimulates the activation of HSCs.

Original languageEnglish
Pages (from-to)950-956
Number of pages7
JournalBiochemical and Biophysical Research Communications
Volume443
Issue number3
DOIs
Publication statusPublished - 2014 Jan 17

Fingerprint

Hepatic Stellate Cells
Transforming Growth Factors
Liver Cirrhosis
Liver
Plasma Kallikrein
Chemical activation
Vascular Endothelial Growth Factor A
Fibrosis
Endothelial cells
Endothelial Cells
Urokinase Plasminogen Activator Receptors
Hepatic Veins
Hydroxyproline
Type C Phospholipases
Conditioned Culture Medium
Phosphatidylinositols
Proteolysis
Smooth Muscle
Muscle
Tail

Keywords

  • Hepatic stellate cells
  • Liver fibrosis
  • Liver sinusoidal endothelial cells
  • Transforming growth factor-β

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Cell Biology
  • Molecular Biology

Cite this

Neovessel formation promotes liver fibrosis via providing latent transforming growth factor-β. / Sakata, Kotaro; Eda, Satoshi; Lee, Eun Seo; Hara, Mitsuko; Imoto, Masaya; Kojima, Soichi.

In: Biochemical and Biophysical Research Communications, Vol. 443, No. 3, 17.01.2014, p. 950-956.

Research output: Contribution to journalArticle

Sakata, Kotaro ; Eda, Satoshi ; Lee, Eun Seo ; Hara, Mitsuko ; Imoto, Masaya ; Kojima, Soichi. / Neovessel formation promotes liver fibrosis via providing latent transforming growth factor-β. In: Biochemical and Biophysical Research Communications. 2014 ; Vol. 443, No. 3. pp. 950-956.
@article{9d2785e27a5d415f865354f21353f7ac,
title = "Neovessel formation promotes liver fibrosis via providing latent transforming growth factor-β",
abstract = "Aim Hepatic fibrosis and angiogenesis occur in parallel during the progression of liver disease. Fibrosis promotes angiogenesis via inducing vascular endothelial growth factor (VEGF) from the activated hepatic stellate cells (HSCs). In turn, increased neovessel formation causes fibrosis, although the underlying molecular mechanism remains undetermined. In the current study, we aimed to address a role of endothelial cells (ECs) as a source of latent transforming growth factor (TGF)-β, the precursor of the most fibrogenic cytokine TGF-β. Methods After recombinant VEGF was administered to mice via the tail vein, hepatic angiogenesis and fibrogenesis were evaluated using immunohistochemical and biochemical analyses in addition to investigation of TGF-β activation using primary cultured HSCs and liver sinusoidal ECs (LSECs). Results In addition to increased hepatic levels of CD31 expression, VEGF-treated mice showed increased α-smooth muscle actin (α-SMA) expression, hepatic contents of hydroxyproline, and latency associated protein degradation products, which reflects cell surface activation of TGF-β via plasma kallikrein (PLK). Liberating the PLK-urokinase plasminogen activator receptor complex from the HSC surface by cleaving a tethering phosphatidylinositol linker with its specific phospholipase C inhibited the activating latent TGF-β present in LSEC conditioned medium and subsequent HSC activation. Conclusion Neovessel formation (angiogenesis) accelerates liver fibrosis at least in part via provision of latent TGF-β that activated on the surface of HSCs by PLK, thereby resultant active TGF-β stimulates the activation of HSCs.",
keywords = "Hepatic stellate cells, Liver fibrosis, Liver sinusoidal endothelial cells, Transforming growth factor-β",
author = "Kotaro Sakata and Satoshi Eda and Lee, {Eun Seo} and Mitsuko Hara and Masaya Imoto and Soichi Kojima",
year = "2014",
month = "1",
day = "17",
doi = "10.1016/j.bbrc.2013.12.074",
language = "English",
volume = "443",
pages = "950--956",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Neovessel formation promotes liver fibrosis via providing latent transforming growth factor-β

AU - Sakata, Kotaro

AU - Eda, Satoshi

AU - Lee, Eun Seo

AU - Hara, Mitsuko

AU - Imoto, Masaya

AU - Kojima, Soichi

PY - 2014/1/17

Y1 - 2014/1/17

N2 - Aim Hepatic fibrosis and angiogenesis occur in parallel during the progression of liver disease. Fibrosis promotes angiogenesis via inducing vascular endothelial growth factor (VEGF) from the activated hepatic stellate cells (HSCs). In turn, increased neovessel formation causes fibrosis, although the underlying molecular mechanism remains undetermined. In the current study, we aimed to address a role of endothelial cells (ECs) as a source of latent transforming growth factor (TGF)-β, the precursor of the most fibrogenic cytokine TGF-β. Methods After recombinant VEGF was administered to mice via the tail vein, hepatic angiogenesis and fibrogenesis were evaluated using immunohistochemical and biochemical analyses in addition to investigation of TGF-β activation using primary cultured HSCs and liver sinusoidal ECs (LSECs). Results In addition to increased hepatic levels of CD31 expression, VEGF-treated mice showed increased α-smooth muscle actin (α-SMA) expression, hepatic contents of hydroxyproline, and latency associated protein degradation products, which reflects cell surface activation of TGF-β via plasma kallikrein (PLK). Liberating the PLK-urokinase plasminogen activator receptor complex from the HSC surface by cleaving a tethering phosphatidylinositol linker with its specific phospholipase C inhibited the activating latent TGF-β present in LSEC conditioned medium and subsequent HSC activation. Conclusion Neovessel formation (angiogenesis) accelerates liver fibrosis at least in part via provision of latent TGF-β that activated on the surface of HSCs by PLK, thereby resultant active TGF-β stimulates the activation of HSCs.

AB - Aim Hepatic fibrosis and angiogenesis occur in parallel during the progression of liver disease. Fibrosis promotes angiogenesis via inducing vascular endothelial growth factor (VEGF) from the activated hepatic stellate cells (HSCs). In turn, increased neovessel formation causes fibrosis, although the underlying molecular mechanism remains undetermined. In the current study, we aimed to address a role of endothelial cells (ECs) as a source of latent transforming growth factor (TGF)-β, the precursor of the most fibrogenic cytokine TGF-β. Methods After recombinant VEGF was administered to mice via the tail vein, hepatic angiogenesis and fibrogenesis were evaluated using immunohistochemical and biochemical analyses in addition to investigation of TGF-β activation using primary cultured HSCs and liver sinusoidal ECs (LSECs). Results In addition to increased hepatic levels of CD31 expression, VEGF-treated mice showed increased α-smooth muscle actin (α-SMA) expression, hepatic contents of hydroxyproline, and latency associated protein degradation products, which reflects cell surface activation of TGF-β via plasma kallikrein (PLK). Liberating the PLK-urokinase plasminogen activator receptor complex from the HSC surface by cleaving a tethering phosphatidylinositol linker with its specific phospholipase C inhibited the activating latent TGF-β present in LSEC conditioned medium and subsequent HSC activation. Conclusion Neovessel formation (angiogenesis) accelerates liver fibrosis at least in part via provision of latent TGF-β that activated on the surface of HSCs by PLK, thereby resultant active TGF-β stimulates the activation of HSCs.

KW - Hepatic stellate cells

KW - Liver fibrosis

KW - Liver sinusoidal endothelial cells

KW - Transforming growth factor-β

UR - http://www.scopus.com/inward/record.url?scp=84893693128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893693128&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2013.12.074

DO - 10.1016/j.bbrc.2013.12.074

M3 - Article

VL - 443

SP - 950

EP - 956

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 3

ER -